2 citations
,
August 2017 in “Dermatologic Therapy” Topical cetirizine 1% increases hair density and may be a promising treatment for hair loss.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
May 2023 in “International journal of science and research” 2% minoxidil solution improved hair density and quality in children with Loose Anagen Hair Syndrome.
March 2023 in “International Journal of Trichology” A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
7 citations
,
August 2025 in “European Journal of Endocrinology” Long-term use of calcineurin inhibitors in transplant patients can cause hormone issues that can be managed with proper care.
1 citations
,
July 1990 in “European Journal of Pharmacology” 6 citations
,
May 2023 in “Molecules” Cepharanthine dry powder inhalers may effectively treat acute lung injury by reducing inflammation.
1 citations
,
May 1992 in “Pharmacological Research” June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
Cepharanthine could be a strong antiviral against COVID-19.
Cadd4 effectively reduces cholesterol levels without side effects.
May 2010 in “Europe PMC (PubMed Central)” Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.
125 citations
,
May 2019 in “Phytomedicine” Cepharanthine is a well-tolerated drug with multiple medical uses, including anti-inflammatory and anti-cancer properties.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Cilostazol may help hair grow and could be a new treatment for hair loss.
8 citations
,
January 2025 in “Gels” The developed nasal gel improves cilostazol delivery to the brain, enhancing its effectiveness and reducing side effects.
17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
June 2024 in “Majallah-i dānishgāh-i ̒ulum-i pizishkī-i Kirmān.” Eucalyptus and Tween 80 most effectively increase cetirizine skin absorption.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
29 citations
,
November 2021 in “FEBS Open Bio” Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
May 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.
2 citations
,
January 2025 in “Journal of Nanobiotechnology” A new engineered treatment shows promise in curing heart fibrosis.
14 citations
,
October 2015 in “Neurochemistry International” Letrozole may help prevent seizures by reducing certain hormone levels.
September 2002 in “Research Repository (Kingston University London)” Mimicking the steroid A-ring may help create effective enzyme inhibitors for prostate disease treatment.
1 citations
,
April 2006 in “International Journal of Oncology” Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
3 citations
,
November 2024 in “Viruses” Cepharanthine may help treat Equid herpesvirus type 8 by reducing oxidative stress.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
July 2025 in “Journal of Investigative Dermatology” 65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.